AN ACT relating to healthcare services and declaring an emergency.
Summary
HB495 is a Kentucky healthcare bill that restricts the use of Medicaid funds for certain gender-affirming medical services. Specifically, it bars the Department for Medicaid Services and its managed care contractors from paying for cross-sex hormones above endogenous levels and for gender reassignment surgery that changes physical characteristics associated with a person’s biological sex, unless federal law requires coverage. The bill is framed as an act relating to healthcare services and includes an emergency clause.
The bill also nullifies Executive Order 2024-632 and any substantially similar administrative action through January 1, 2028. In effect, it prevents executive-branch directives from requiring or authorizing Medicaid coverage for the prohibited services during that period. The legislation was enacted over a gubernatorial veto, with the veto overridden on March 27, 2025.
Impact
HB495 amends Kentucky law by creating a new section in KRS Chapter 205 governing Medicaid expenditures. It limits state Medicaid spending and the spending of Medicaid managed care organizations on specified gender-affirming treatments, while preserving compliance with any conflicting federal requirements. The bill also overrides Executive Order 2024-632 and similar directives, reducing executive-branch authority to direct Medicaid coverage for these services through January 1, 2028. Affected parties include Medicaid recipients seeking gender-affirming care, the Department for Medicaid Services, and managed care organizations administering Medicaid benefits.
Sentiment
The voting history shows the bill had enough support to pass both chambers and ultimately survive a veto override, indicating strong legislative backing. House and Senate votes on third reading were generally favorable, though not unanimous, suggesting meaningful opposition remained. The emergency designation and override of the veto indicate the bill’s supporters viewed it as urgent and important, while opponents likely objected to its restrictions on gender-affirming care and its interference with executive policy.
Contention
The main point of contention is the bill’s restriction on Medicaid coverage for gender-affirming treatments, especially cross-sex hormones and gender reassignment surgery. Supporters appear to have framed the measure as a healthcare and policy limitation consistent with protecting state funds and legislative authority, while opponents likely viewed it as discriminatory and harmful to transgender Medicaid beneficiaries. Another contested issue is the bill’s nullification of Executive Order 2024-632 and similar directives, which directly pits the legislature against executive-branch policymaking.